drugset / Trial / NCT01090817

An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease

NCT01090817

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Despite the advent of newer biologic therapies such as infliximab for Crohn's disease, a form of autoimmune inflammatory bowel disease, a proportion of patients are refractory to such therapy and require surgery. The hypothesis is that mesenchymal stromal cell therapy using third party human cultured cells will be safe and effective

Timeline

Start
2010-01
Primary completion
2014-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 2e+06 cells/kg Intravenous

Indications